Business context and reporting period
This is ReWalk Robotics Ltd.’s Form 10-K for the fiscal year ended December 31, 2015, filed February 29, 2016—not a standalone fourth-quarter report. The filing describes an Israeli medical-device company that develops and sells wearable exoskeletons for people with paraplegia. Its products are ReWalk Personal, for home and community use, and ReWalk Rehabilitation, for clinical settings. The filing identifies the issuer as ReWalk Robotics Ltd.; this differs from the request metadata naming Lifeward Ltd.
At year-end, the company reported 104 units placed in rehabilitation centers and 107 for home or community use. Its commercial focus was shifting toward Personal systems and third-party reimbursement.
Financial and operating metrics
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Revenue | $3.746 million | $3.951 million |
| Gross profit (loss) | $0.214 million; 6% margin | $(0.621) million; (16)% margin |
| Operating expenses | $25.388 million | $19.304 million |
| Operating loss | $(25.174) million | $(19.925) million |
| Net loss | $(25.415) million | $(21.668) million |
| Net loss per share | $(2.10) | $(6.34) |
| Cash used in operating activities | $(25.180) million | $(15.319) million |
| Cash and cash equivalents at year-end | $17.869 million | $41.829 million |
| Total assets / shareholders’ equity | $25.574 million / $20.920 million | $47.665 million / $43.853 million |
Revenue by product in 2015 was $2.766 million from Personal systems and $0.980 million from Rehabilitation systems. The company placed 73 units in 2015 (53 Personal, 20 Rehabilitation), compared with 74 units in 2014 (43 Personal, 31 Rehabilitation). The United States generated $2.439 million of 2015 revenue, Europe $0.820 million, and Asia-Pacific $0.487 million.
At December 31, 2015, current assets were $23.776 million and current liabilities were $4.343 million. Total liabilities were $4.654 million. The filing reports no funded Kreos loan balance at year-end; the initial $12 million facility draw occurred January 4, 2016.
Material changes versus the prior comparable period
- Revenue declined 5%, as Personal-system revenue rose 26% to $2.766 million while Rehabilitation revenue fell 44% to $0.980 million.
- Gross performance improved by $0.835 million, moving from a gross loss to positive gross profit. Management attributed the improvement to completing the manufacturing transition to Sanmina and economies of scale, partly offset by transition costs for the ReWalk Personal 6.0 model. FY 2014 included a $0.466 million BIRD grant settlement charge.
- Operating expenses increased 32%. Sales and marketing rose 77% to $13.056 million, and general and administrative expenses rose 91% to $6.395 million. Research and development fell 31% to $5.937 million, primarily because FY 2014 included a one-time, non-cash share-based compensation award.
- Operating cash use increased by $9.861 million, and year-end cash fell by $23.960 million. The company attributed the higher operating cash use primarily to increased operating expenses and working-capital changes.
Outlook, risks, contingencies and unusual items
- Management said year-end cash resources, together with anticipated resources, were sufficient for at least the next 12 months. It expected continued net losses and negative operating cash flow in the near term, with spending focused on sales, marketing, reimbursement efforts and product development. No numerical revenue or earnings guidance was provided.
- On December 30, 2015, the company entered a secured Kreos facility of up to $20 million. It drew $12 million gross on January 4, 2016; the notes report $10.924 million received net of transaction fees and an advance payment. The facility carries 10.75% annual interest and a first-priority lien over substantially all assets, including intellectual property. Up to another $8 million may be drawn in qualifying tranches if the company raises at least $10 million through an issuance of capital stock or convertible debt before December 31, 2016.
- In December 2015, the U.S. Veterans’ Administration issued a national evaluation, training and procurement policy for qualifying veterans using ReWalk Personal—the first U.S. national coverage policy for the product, according to the company. Private-insurer coverage remained case-by-case, and broad reimbursement was uncertain.
- In February 2016, after year-end, the FDA cited deficiencies in the protocol for the mandatory post-market study of ReWalk Personal 6.0 and stated it believed a second premarket notification should be submitted. The company intended to discuss the letter with the FDA and expected to address study-protocol deficiencies, but warned enforcement could prevent U.S. sales.
- Management cited substantial risks: an early and unproven market, limited long-term clinical evidence for claimed secondary health benefits, dependence on reimbursement, competition, and reliance on a single contract manufacturer and supplier chain. One customer accounted for 14.8% of 2015 revenue.
- A product-injury claim filed in 2013 was settled in April 2015; the company said the settlement had no material effect. The filing reports no pending legal matter expected to have a material adverse effect. The 2015 financial statements received an unqualified audit opinion; management assessed internal control over financial reporting as effective, without an auditor attestation.
Investor verification priorities
- Confirm the issuer identity and filing period: the source is ReWalk Robotics Ltd.’s FY 2015 Form 10-K, not a Lifeward Ltd. filing or a standalone Q4 report.
- Track the FDA’s response to the February 2016 letter, the post-market study protocol, any second premarket submission, and the status of U.S. sales of Personal 6.0.
- Verify the practical implementation, eligibility criteria and payment economics of the VA policy, and whether private-payor coverage is expanding.
- Reconcile cash runway and financing needs against operating cash use, including the Kreos draw, interest, secured collateral and conditions for further draws.
- Assess sustainable unit economics and margins as product mix, production volumes and manufacturing costs change; also monitor customer concentration and dependence on Sanmina.
- Check the filing’s differing OCS contingent-liability figures: approximately $300,000 in one discussion versus $290,000 in the financial-statement note.